Effect of Vitamin D Supplementation on Brain Waves in Female Major Depressive Disorder Patients With Hypovitaminosis D
NCT07579078
Avitaminosis, Deficiency Diseases
Dhaka, Bangladesh
View Trial DetailsNCT Number: NCT05214040
Hypovitaminosis D is common in the adult population, it affects at least 1 billion people worldwide, and in particular 80% of the French population according to the National Institute for Public Health Surveillance. Hypovitaminosis D is accompanied or complicated by deleterious health manifestations such as bone, immune and cancer diseases, neuromuscular disorders and a propensity to fall, for example. Hypovitaminosis D has also been associated with more complicated care pathways (increase in the severity of the reason for hospitalization, length of hospitalization, risk of in-hospital death). Prevention of these clinical events depends on correcting vitamin D status.
In sick, dependent or fragile adults, natural intakes are generally insufficient. It is indeed accepted that hypovitaminosis D may not be treated effectively by dietary measures or by simple exposure to the sun in French latitudes. Drug supplementation is therefore necessary, with the objective of achieving a target concentration of circulating 25-hydroxyvitamin D (25 (OH) D) of 75 nmol / L (30 ng / mL) in this population.
Vitamin D supplementation, when properly conducted, corrects hypovitaminosis D, and has been associated with improved prognosis, especially life-saving, in therapeutic trials versus placebo. Such results lead the investigators to suggest that the identification and correction of hypovitaminosis D in hospitalized patients could represent a simple, effective and inexpensive strategy for improving hospital care pathways. In this perspective, the first step is to determine the prevalence, severity and clinical profile of hospitalized patients with hypovitaminosis D, as well as their course of care. To the investigators knowledge, there are no large-scale studies based on real-life data on this subject.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: baseline
the prevalence of hypovitaminosis D will be calculated for each of the 3 definition thresholds for hypovitaminosis D found in the literature: ≤ 75 nmol/L, ≤ 50 nmol/L and ≤ 25 nmol/L.
Time frame: baseline
The clinical profile will be determine by the data provided by the physician during the hospitalization or the consultation
Time frame: baseline
determine whether the circulating 25-hydroxyvitamin D concentration is associated with the length of hospitalization in days
Time frame: baseline, 14 and 28 days, 3 and 6 months after the dosage
determine whether the circulating 25-hydroxyvitamin D concentration is associated with the death occurring during hospital stay.
Contact information is provided by the study sponsor or research team.
University Hospital, Angers
Other Gov
Acronym: VIVALDI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07579078
Avitaminosis, Deficiency Diseases
Dhaka, Bangladesh
View Trial DetailsNCT06481111
Avitaminosis, Deficiency Diseases
Milan, Italy
View Trial DetailsNCT06138249
Avitaminosis, Deficiency Diseases
Bari, Italy
View Trial DetailsNCT07199829
Avitaminosis, Deficiency Diseases
Tacoma, Washington, United States
View Trial Details